Purple Biotech Ltd (KTOV) - Total Assets
Based on the latest financial reports, Purple Biotech Ltd (KTOV) holds total assets worth ILA85.78 Million ILA (≈ $229.98K USD) as of June 2020. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Purple Biotech Ltd shareholders equity for net asset value and shareholders' equity analysis.
Purple Biotech Ltd - Total Assets Trend (2009–2019)
This chart illustrates how Purple Biotech Ltd's total assets have evolved over time, based on quarterly financial data.
Purple Biotech Ltd - Asset Composition Analysis
Current Asset Composition (December 2019)
Purple Biotech Ltd's total assets of ILA85.78 Million consist of 56.4% current assets and 43.6% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 29.8% |
| Accounts Receivable | ILA3.49 Million | 23.7% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA244.00K | 1.7% |
| Intangible Assets | ILA6.17 Million | 41.9% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2009–2019)
This chart illustrates how Purple Biotech Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Purple Biotech Ltd (KTOV) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Purple Biotech Ltd's current assets represent 56.4% of total assets in 2019, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 29.8% of total assets in 2019, up from 0.2% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, a decrease from 47.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 41.9% of total assets.
Purple Biotech Ltd Competitors by Total Assets
Key competitors of Purple Biotech Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pluristem
TA:PSTI
|
Israel | ILA79.13 Million |
|
Hadasit Bio
TA:HDST
|
Israel | ILA14.67 Million |
|
Peptron Inc
KQ:087010
|
Korea | ₩183.74 Billion |
|
MEDIPOST Co. Ltd
KQ:078160
|
Korea | ₩374.57 Billion |
|
Bioneer Corporation
KQ:064550
|
Korea | ₩376.52 Billion |
|
Macrogen Inc
KQ:038290
|
Korea | ₩341.60 Billion |
|
Cell Biotech Co. Ltd
KQ:049960
|
Korea | ₩134.57 Billion |
|
Panagene Inc
KQ:046210
|
Korea | ₩101.91 Billion |
Purple Biotech Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.22 | 1.99 | 11.70 |
| Quick Ratio | 2.22 | 1.99 | 11.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA35.78 Million | ILA5.30 Million | ILA13.62 Million |
Purple Biotech Ltd - Advanced Valuation Insights
This section examines the relationship between Purple Biotech Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.27 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | ILA14.72 Million |
| Market Capitalization | $461.41K USD |
Valuation Analysis
Below Book Valuation: The market values Purple Biotech Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Purple Biotech Ltd's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Purple Biotech Ltd (2009–2019)
The table below shows the annual total assets of Purple Biotech Ltd from 2009 to 2019.
| Year | Total Assets | Change |
|---|---|---|
| 2019-12-31 | ILA14.72 Million ≈ $39.46K |
-0.03% |
| 2018-12-31 | ILA14.72 Million ≈ $39.47K |
+3.81% |
| 2017-12-31 | ILA14.18 Million ≈ $38.02K |
-4.90% |
| 2016-12-31 | ILA14.91 Million ≈ $39.98K |
+37.94% |
| 2015-12-31 | ILA10.81 Million ≈ $28.99K |
+514.67% |
| 2014-12-31 | ILA1.76 Million ≈ $4.72K |
+465.59% |
| 2013-12-31 | ILA311.00K ≈ $833.78 |
-95.92% |
| 2011-12-31 | ILA7.62 Million ≈ $20.42K |
-19.65% |
| 2010-12-31 | ILA9.48 Million ≈ $25.41K |
-28.45% |
| 2009-12-31 | ILA13.25 Million ≈ $35.52K |
-- |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension i… Read more